Invion Limited (IVX.AX)

AUD 0.26

(-7.14%)

Market Cap (In AUD)

18 Million

Revenue (In AUD)

3.69 Million

Net Income (In AUD)

-5.62 Million

Avg. Volume

3.4 Million

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.105-0.7
PE
-
EPS
-
Beta Value
1.258
ISIN
AU000000IVX4
CUSIP
Q4976G108
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Thian Chew
Employee Count
-
Website
https://www.inviongroup.com
Ipo Date
2010-02-14
Details
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.

More Stocks